News
Need for Early Intervention in COPD − A Suitable Time for Mucolytic Treatment
Chronic Obstructive Pulmonary Disease (COPD) ranks third among the leading causes of morbidity and mortality worldwide, with more than 210 million people expected to be affected by 2030. While common, it is preventable and treatable. The mucolytic erdosteine has proven to be an effective helper in COPD therapy.
What Did 3 Years of Data from the Czech National COPD Database Reveal?
In December of last year, the Czech multicenter research database on COPD was completed. This was…
COPD is Treated Differently Across Europe – What Could Be the Reasons for This Variability?
As part of this year's Hradec Pneumological Days (HPD 2022), the head of the Pulmonary Clinic at…
Prolonged Course of Metastatic Stomach Cancer with Long-term Stabilization – Case Report
In the following case report, we present the case of a patient with a prolonged oncological disease…
Focused on MS: Statistics Are Boring, But They Have Valuable Data!
What is the prevalence of multiple sclerosis? Has the proportion of patients treated with highly…
Epstein-Barr Virus – Is the Culprit of MS Revealed?
Could the Epstein-Barr virus hold the answer to the etiology of multiple sclerosis? A dataset of…
From Biomarker Testing to NSCLC Treatment Selection
During a satellite symposium at this year's European Lung Cancer Congress (ELCC 2022), Prof. Martin…
Is Adding Fibrinogen Concentrate to Transfusion Therapy for Postpartum Hemorrhage an Effective Approach?
Significant postpartum hemorrhage can be managed with fresh frozen plasma transfusion. However,…
Administration of Fibrinogen Concentrate in Patients with Persistent Bleeding After Cardiac Surgery
Is the administration of fibrinogen concentrate in patients with persistent bleeding after initial…
Treatment of a patient with colorectal cancer after kidney transplantation – case report
Patients after organ transplantation currently live to an older age thanks to advances in surgery…